2023 World Conference on Lung Cancer (Posters)-P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study

P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a study presented at the WCLC 2023 conference. The study evaluated the effectiveness and safety profile of Lurbinectedin in second-line small cell lung cancer (SCLC) treatment using real-world evidence. Lurbinectedin is an inhibitor of oncogenic transcription that received accelerated approval from the US FDA in 2020.<br /><br />The study included patients from a nationwide electronic health record database who received Lurbinectedin monotherapy as a second-line treatment for SCLC between 2020 and 2022. The effectiveness of the treatment was evaluated based on overall response rates, progression-free survival, and time to next treatment. Safety outcomes such as neutropenia, thrombocytopenia, anemia, and febrile neutropenia were also assessed.<br /><br />The study found that out of 447 patients who received Lurbinectedin, 374 were included in the effectiveness cohort and 323 in the safety cohort. The real-world overall response rate was 27.5%, with a median duration of response of 2.7 months. Other effectiveness outcomes, such as progression-free survival and time to next treatment, were also analyzed.<br /><br />In terms of safety, grade 3 neutropenia, thrombocytopenia, anemia, and febrile neutropenia were reported in a small percentage of patients. The study also observed that the rates of these adverse events tended to be lower than what was observed in the phase 2 basket trial.<br /><br />Overall, the study concluded that the real-world effectiveness and safety outcomes of Lurbinectedin in second-line SCLC treatment were generally consistent with the results of the phase 2 trial. The study provides valuable real-world evidence for the use of Lurbinectedin in this patient population.

Asset Subtitle

Apar Kishor Ganti

Meta Tag

Speaker Apar Kishor Ganti

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

WCLC 2023 conference

Lurbinectedin

second-line small cell lung cancer

real-world evidence

oncogenic transcription inhibitor

accelerated approval

overall response rates

progression-free survival

time to next treatment

safety outcomes